Study Summary
The goal of this clinical trial is to learn about the safety, and tolerability of giving an experimental gene therapy called SPX-01 to an infant with spinal muscular atrophy (SMA) type 1. SMA type 1 is a rare inherited disease that causes severe muscle weakness and can affect breathing, swallowing, and movement. SPX-01 is designed to deliver a working copy of a gene called SMN1, which does not function properly in children with SMA. The main questions this study aims to answer are: * What side effects or medical problems occur after SPX-01 is given? * What changes in the infant's movement, breathing, and overall health are observed during follow-up? One infant aged 6 months or younger with genetically confirmed SMA type 1 will take part in this study. The infant will: * Receive a single dose of SPX-01 through a vein over approximately one hour. * Attend follow-up visits over 12 months, including medical examinations, blood tests, and assessments of movement and breathing.
Interested in this trial?
Submit an InquiryInterventions
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Medical Center | Tehran | Tehran Province | Iran |